ERBB2 and glioblastoma: Presently, initial clinical experiences of CAR-T therapy for GBM have only three target antigens (EGFRvIII, HER2 and IL-13Rα2, which are short for epidermal growth factor receptor variant III, human epidermal growth factor receptor 2, and interleukin-13 receptor alpha 2 respectively) [9].